David L. Lowrance net worth and biography

David Lowrance Biography and Net Worth

CFO of Savara

Mr. Lowrance has served as Savara’s Chief Financial and Administrative Officer since December 2022 and Chief Financial Officer since November 2016. Previously, Mr. Lowrance was the Chief Financial Officer and Treasurer of Edgemont Pharmaceuticals, a fully integrated specialty pharmaceutical company. Prior to that, Mr. Lowrance served as the Chief Financial Officer and Secretary of Acucela Inc., a clinical-stage biotechnology company, where he was responsible for overseeing all aspects of the day-to-day operations, business development and growth endeavors, investor relations, and corporate communications. While there, Mr. Lowrance helped lead a $162 million international IPO, with a listing on the Tokyo Stock Exchange. Earlier in his career, Mr. Lowrance was Vice President and Chief Financial Officer of Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, where he oversaw all aspects of finance and accounting, business and growth strategy, and product development. Mr. Lowrance holds a CPA and has a B.B.A. in Accounting from the University of Georgia.

What is David L. Lowrance's net worth?: The estimated net worth of David L. Lowrance is at least $818.23 thousand as of December 28th, 2023. Lowrance owns 342,355 shares of Savara stock worth more than $818,228 as of July 12th. This net worth evaluation does not reflect any other assets that Lowrance may own. Learn More about David L. Lowrance's net worth.
How old is David L. Lowrance?: Lowrance is currently 50 years old. There are 7 older executives and no younger executives at Savara. Learn More on David L. Lowrance's age.
How do I contact David L. Lowrance?: The corporate mailing address for Lowrance and other Savara executives is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. Savara can also be reached via phone at 512-614-1848 and via email at [email protected]. Learn More on David L. Lowrance's contact information.
Has David L. Lowrance been buying or selling shares of Savara?: David L. Lowrance has not been actively trading shares of Savara during the last ninety days. Most recently, David L. Lowrance sold 10,000 shares of the business's stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $4.71, for a transaction totalling $47,100.00. Following the completion of the sale, the chief financial officer now directly owns 342,355 shares of the company's stock, valued at $1,612,492.05. Learn More on David L. Lowrance's trading history.
Who are Savara's active insiders?: Savara's insider roster includes Badrul Chowdhury (Insider), Nevan Elam (Director), Richard Hawkins (Director), David Lowrance (CFO), Joseph Mccracken (Director), Matthew Pauls (CEO), Raymond Pratt (Insider), and David Ramsay (Director). Learn More on Savara's active insiders.
Are insiders buying or selling shares of Savara?: In the last twelve months, Savara insiders bought shares 3 times. They purchased a total of 78,225 shares worth more than $178,179.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 54,702 shares worth more than $181,063.62. The most recent insider tranaction occured on June, 20th when Director Richard J Hawkins bought 48,225 shares worth more than $98,379.00. Insiders at Savara own 5.3% of the company. Learn More about insider trades at Savara.
Information on this page was last updated on 6/20/2025.

David L. Lowrance Insider Trading History at Savara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/28/2023	Sell	10,000	$4.71	$47,100.00	342,355
3/15/2021	Buy	13,793	$1.45	$19,999.85	13,793
5/2/2019	Sell	7,500	$10.79	$80,925.00	3,800
4/8/2019	Sell	7,500	$9.02	$67,650.00	2,446
4/4/2019	Sell	2,446	$9.00	$22,014.00	2,446
11/1/2018	Sell	18,480	$9.22	$170,385.60
6/12/2018	Sell	5,275	$12.08	$63,722.00	23,080
6/8/2018	Sell	675	$12.13	$8,187.75	23,080
2/15/2018	Sell	7,000	$12.88	$90,160.00	33,994
6/7/2017	Buy	2,100	$4.75	$9,975.00	2,100

David L. Lowrance Buying and Selling Activity at Savara

Savara Company Overview

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Today's Range

Now: $2.39

$2.24

$2.43

50 Day Range

MA: $2.49

$1.94

$3.28

2 Week Range

Now: $2.39

$1.89

$5.11

Volume

1,084,233 shs

Average Volume

1,273,335 shs

Market Capitalization

$413.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

David Lowrance Biography and Net Worth

What is David L. Lowrance's net worth?

How old is David L. Lowrance?

How do I contact David L. Lowrance?

Has David L. Lowrance been buying or selling shares of Savara?

Who are Savara's active insiders?

Are insiders buying or selling shares of Savara?